CELIX PHARMA LTd
- Awards
- 4
- Value outside frameworks
- Framework places only
- Framework places
- 4
Values exclude VAT where the notices give it, and only values in pounds are added up. A framework place carries the framework's whole ceiling, shared with the other suppliers on it, so framework places are counted rather than added up. Every award here is a framework place.
Awards
| Procurement | Buyer | Value | Date |
|---|---|---|---|
| NHS National Framework for Transition Products (Nintedanib and Dalbavancin) Lot 1 framework | NHS England | £14,758,000 | 27 Mar 2026 |
| NHS National Framework for Transition Products (Nintedanib and Dalbavancin) Lot 1 framework | NHS England | £14,758,000 | 25 Feb 2026 |
| NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin Lot 1 framework | NHS England | £25,881,000 | 5 Jan 2026 |
| NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin Lot 1 framework | NHS England | £25,881,000 | 25 Nov 2025 |
Top buyers
| Buyer | Awards | Value |
|---|---|---|
| NHS England | 4 | - |
By number of awards. Value is the total of awards made to this supplier alone outside frameworks, excluding VAT where the notices give it.